Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Account Payables (2022 - 2025)

Historic Change in Account Payables for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $1.3 million.

  • Entrada Therapeutics' Change in Account Payables rose 51687.9% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 24918.33%. This contributed to the annual value of $991000.0 for FY2024, which is 13532.98% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Change in Account Payables of $1.3 million as of Q3 2025, which was up 51687.9% from -$321000.0 recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Change in Account Payables high stood at $4.6 million for Q4 2022, and its period low was -$4.4 million during Q2 2023.
  • For the 4-year period, Entrada Therapeutics' Change in Account Payables averaged around $170066.7, with its median value being -$314000.0 (2024).
  • Its Change in Account Payables has fluctuated over the past 5 years, first tumbled by 38441.56% in 2023, then soared by 51687.9% in 2025.
  • Entrada Therapeutics' Change in Account Payables (Quarter) stood at $4.6 million in 2022, then crashed by 47.62% to $2.4 million in 2023, then increased by 18.29% to $2.8 million in 2024, then crashed by 54.01% to $1.3 million in 2025.
  • Its Change in Account Payables was $1.3 million in Q3 2025, compared to -$321000.0 in Q2 2025 and -$1.9 million in Q1 2025.